HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Free Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (8) Citing Articles via Google Scholar Google Scholar Articles by Kogai, T Articles by Brent, G A Search for Related Content PubMed PubMed Citation Articles by Kogai, T Articles by Brent, G A

Molecular Endocrinology Laboratory, VA Greater Los Angeles Healthcare System, Departments of Medicine and Physiology, David Geffen School of Medicine at UCLA, Los Angeles, California 90073, USA
¹ Third Department of Medicine, Yamanashi University, Yamanashi 409-3898, Japan

(Requests for offprints should be addressed to G A Brent; Email: gbrent{at}ucla.edu)

The sodium/iodide symporter (NIS) mediates iodide uptake in the thyroid gland and lactating breast. NIS mRNA and protein expression are detected in most thyroid cancer specimens, although functional iodide uptake is usually reduced resulting in the characteristic finding of a ‘cold’ or non-functioning lesion on a radioiodine image. Iodide uptake after thyroid stimulating hormone (TSH) stimulation, however, is sufficient in most differentiated thyroid cancer to utilize ß-emitting radioactive iodide for the treatment of residual and metastatic disease. Elevated serum TSH, achieved by thyroid hormone withdrawal in athyreotic patients or after recombinant human thyrotropin administration, directly stimulates NIS gene expression and/or NIS trafficking to the plasma membrane, increasing radioiodide uptake. Approximately 10–20% differentiated thyroid cancers, however, do not express the NIS gene despite TSH stimulation. These tumors are generally associated with a poor prognosis. Reduced NIS gene expression in thyroid cancer is likely due in part, to impaired trans-activation at the proximal promoter and/or the upstream enhancer. Basal NIS gene expression is detected in about 80% breast cancer specimens, but the fraction with functional iodide transport is relatively low. Lactogenic hormones and various nuclear hormone receptor ligands increase iodide uptake in breast cancer cells in vitro, but TSH has no effect. A wide range of ‘differentiation’ agents have been utilized to stimulate NIS expression in thyroid and breast cancer using in vitro and in vivo models, and a few have been used in clinical studies. Retinoic acid has been used to stimulate NIS expression in both thyroid and breast cancer. There are similarities and differences in NIS gene regulation and expression in thyroid and breast cancer. The various agents used to enhance NIS expression in thyroid and breast cancer will be reviewed with a focus on the mechanism of action. Agents that promote tumor differentiation, or directly stimulate NIS gene expression, may result in iodine concentration in ‘scan-negative’ thyroid cancer and some breast cancer.

This article has been cited by other articles:

				T. Kogai, S. Sajid-Crockett, L. S Newmarch, Y.-Y. Liu, and G. A Brent Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells J. Endocrinol., November 1, 2008; 199(2): 243 - 252. [Abstract] [Full Text] [PDF]

				E. Ferretti, E. Tosi, A. Po, A. Scipioni, R. Morisi, M. S. Espinola, D. Russo, C. Durante, M. Schlumberger, I. Screpanti, et al. Notch Signaling Is Involved in Expression of Thyrocyte Differentiation Markers and Is Down-Regulated in Thyroid Tumors J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 4080 - 4087. [Abstract] [Full Text] [PDF]

				N. Shcheynikov, D. Yang, Y. Wang, W. Zeng, L. P. Karniski, I. So, S. M. Wall, and S. Muallem The Slc26a4 transporter functions as an electroneutral Cl-/I-/HCO3- exchanger: role of Slc26a4 and Slc26a6 in I- and HCO3- secretion and in regulation of CFTR in the parotid duct J. Physiol., August 15, 2008; 586(16): 3813 - 3824. [Abstract] [Full Text] [PDF]

				T. Kogai, E. Ohashi, M. S. Jacobs, S. Sajid-Crockett, M. L. Fisher, Y. Kanamoto, and G. A. Brent Retinoic Acid Stimulation of the Sodium/Iodide Symporter in MCF-7 Breast Cancer Cells Is Meditated by the Insulin Growth Factor-I/Phosphatidylinositol 3-Kinase and p38 Mitogen-Activated Protein Kinase Signaling Pathways J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1884 - 1892. [Abstract] [Full Text] [PDF]

				E. D. McLanahan, M. E. Andersen, and J. W. Fisher A Biologically Based Dose-Response Model for Dietary Iodide and the Hypothalamic-Pituitary-Thyroid Axis in the Adult Rat: Evaluation of Iodide Deficiency Toxicol. Sci., April 1, 2008; 102(2): 241 - 253. [Abstract] [Full Text] [PDF]

				N. Tran, L. Valentin-Blasini, B. C. Blount, C. G. McCuistion, M. S. Fenton, E. Gin, A. Salem, and J. M. Hershman Thyroid-stimulating hormone increases active transport of perchlorate into thyroid cells Am J Physiol Endocrinol Metab, April 1, 2008; 294(4): E802 - E806. [Abstract] [Full Text] [PDF]

				H. Li, K. Richard, B. McKinnon, and R. H. Mortimer Effect of Iodide on Human Choriogonadotropin, Sodium-Iodide Symporter Expression, and Iodide Uptake in BeWo Choriocarcinoma Cells J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 4046 - 4051. [Abstract] [Full Text] [PDF]